PepGen Inc.

Good afternoon and welcome to PEPGEN's fourth quarter and full year 2023 earnings call to discuss its financial results and recent corporate developments. At this time, all participants are in a listen-only mode. Following the manager's prepared remarks, we will hold a question and answer session. To ask a question during the session, ask a question at that time, please press star followed by 11 on your touchtone phone. As a reminder, this call is being recorded today, Thursday, March 6, 2024. I would now like to turn the conference call over to Emiko Bryant, Chief of Staff of PEPGEN.

Emiko, please go ahead.

Thank you, operator. Good afternoon, everyone, and thank you for joining today's call. Earlier today, we released our financial results for the fourth quarter and full year 2023 and provided an update on recent corporate developments. The press release and our 10-K files with the SEC this afternoon outlining our financial results are both available on our website at pepgen.com. Joining me on the call today are James McArthur, PhD, President and Chief Executive Officer, Dr. Michelle Melian, Senior Vice President, Head of Clinical Development, and Noel Donnelly, Chief Financial Officer. As a reminder, we will be making forward-looking statements regarding our financial outlook in addition to regulatory and product development plans and research activities. These statements are subject to risks and uncertainties that may cause actual results to materially differ from those forecasted. A description of these risks can be found in our most recent 10-K on file with the SEC. PEPGEN does not undertake any obligation to publicly update its forward-looking statements as a result of new information, future events, or changes in its expectations. I will now turn the call over to our CEO, James MacArthur. James?